Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model

Rajasubramaniam Shanmugam, Vetrichelvan Jayaprakasan, Yesim Gokmen-Polar, Stephanie Kelich, Kathy D. Miller, Michele Yip-Schneider, Liang Cheng, Poornima Bhat-Nakshatri, George W. Sledge, Harikrishna Nakshatri, Qi Huang Zheng, Michael A. Miller, Timothy R DeGrado, Gary D. Hutchins, Christopher J. Sweeney

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

BACKGROUND. Nuclear Factor kappa B (NFκB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P). METHODS. The in vitro effects of P were assessed using the androgen independent cell line, CWR22Rv1, and human umbilical endothelial cells (HUVECs). The in vivo activity of P as a single agent and its ability to augment the efficacy of docetaxel and the anti-androgen, bicalutamide, were determined using the CWR22Rv1 xenograft model. RESULTS. Parthenolide at low micromolar concentration inhibited proliferation of CWR22Rv1 and HUVEC cells, promoted apoptosis and abrogated NFκB-DNA binding. Parthenolide downregulated anti-apoptotic genes under NFκB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). Parthenolide also augmented the in vivo efficacy of docetaxel and restored sensitivity to anti-androgen therapy. CONCLUSION. These studies demonstrate parthenolide's anti-tumor and anti-angiogenic activity, and its potential to augment the efficacy of chemotherapy and hormonal therapy.

Original languageEnglish (US)
Pages (from-to)1498-1511
Number of pages14
JournalProstate
Volume66
Issue number14
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Heterografts
docetaxel
Prostatic Neoplasms
Hormones
Drug Therapy
Androgens
NF-kappa B
B-Form DNA
Umbilicus
Sesquiterpenes
Human Umbilical Vein Endothelial Cells
Lactones
Neoplasms
Transcription Factors
Phosphotransferases
Down-Regulation
Endothelial Cells
parthenolide
Apoptosis
Cell Line

Keywords

  • Angiogenesis
  • Anti-tumor
  • NFκB
  • Parthenolide

ASJC Scopus subject areas

  • Urology

Cite this

Shanmugam, R., Jayaprakasan, V., Gokmen-Polar, Y., Kelich, S., Miller, K. D., Yip-Schneider, M., ... Sweeney, C. J. (2006). Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate, 66(14), 1498-1511. https://doi.org/10.1002/pros.20482

Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. / Shanmugam, Rajasubramaniam; Jayaprakasan, Vetrichelvan; Gokmen-Polar, Yesim; Kelich, Stephanie; Miller, Kathy D.; Yip-Schneider, Michele; Cheng, Liang; Bhat-Nakshatri, Poornima; Sledge, George W.; Nakshatri, Harikrishna; Zheng, Qi Huang; Miller, Michael A.; DeGrado, Timothy R; Hutchins, Gary D.; Sweeney, Christopher J.

In: Prostate, Vol. 66, No. 14, 01.10.2006, p. 1498-1511.

Research output: Contribution to journalArticle

Shanmugam, R, Jayaprakasan, V, Gokmen-Polar, Y, Kelich, S, Miller, KD, Yip-Schneider, M, Cheng, L, Bhat-Nakshatri, P, Sledge, GW, Nakshatri, H, Zheng, QH, Miller, MA, DeGrado, TR, Hutchins, GD & Sweeney, CJ 2006, 'Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model', Prostate, vol. 66, no. 14, pp. 1498-1511. https://doi.org/10.1002/pros.20482
Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M et al. Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate. 2006 Oct 1;66(14):1498-1511. https://doi.org/10.1002/pros.20482
Shanmugam, Rajasubramaniam ; Jayaprakasan, Vetrichelvan ; Gokmen-Polar, Yesim ; Kelich, Stephanie ; Miller, Kathy D. ; Yip-Schneider, Michele ; Cheng, Liang ; Bhat-Nakshatri, Poornima ; Sledge, George W. ; Nakshatri, Harikrishna ; Zheng, Qi Huang ; Miller, Michael A. ; DeGrado, Timothy R ; Hutchins, Gary D. ; Sweeney, Christopher J. / Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. In: Prostate. 2006 ; Vol. 66, No. 14. pp. 1498-1511.
@article{ec304300f359495aa82bf77fdc208783,
title = "Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model",
abstract = "BACKGROUND. Nuclear Factor kappa B (NFκB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P). METHODS. The in vitro effects of P were assessed using the androgen independent cell line, CWR22Rv1, and human umbilical endothelial cells (HUVECs). The in vivo activity of P as a single agent and its ability to augment the efficacy of docetaxel and the anti-androgen, bicalutamide, were determined using the CWR22Rv1 xenograft model. RESULTS. Parthenolide at low micromolar concentration inhibited proliferation of CWR22Rv1 and HUVEC cells, promoted apoptosis and abrogated NFκB-DNA binding. Parthenolide downregulated anti-apoptotic genes under NFκB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). Parthenolide also augmented the in vivo efficacy of docetaxel and restored sensitivity to anti-androgen therapy. CONCLUSION. These studies demonstrate parthenolide's anti-tumor and anti-angiogenic activity, and its potential to augment the efficacy of chemotherapy and hormonal therapy.",
keywords = "Angiogenesis, Anti-tumor, NFκB, Parthenolide",
author = "Rajasubramaniam Shanmugam and Vetrichelvan Jayaprakasan and Yesim Gokmen-Polar and Stephanie Kelich and Miller, {Kathy D.} and Michele Yip-Schneider and Liang Cheng and Poornima Bhat-Nakshatri and Sledge, {George W.} and Harikrishna Nakshatri and Zheng, {Qi Huang} and Miller, {Michael A.} and DeGrado, {Timothy R} and Hutchins, {Gary D.} and Sweeney, {Christopher J.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1002/pros.20482",
language = "English (US)",
volume = "66",
pages = "1498--1511",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "14",

}

TY - JOUR

T1 - Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model

AU - Shanmugam, Rajasubramaniam

AU - Jayaprakasan, Vetrichelvan

AU - Gokmen-Polar, Yesim

AU - Kelich, Stephanie

AU - Miller, Kathy D.

AU - Yip-Schneider, Michele

AU - Cheng, Liang

AU - Bhat-Nakshatri, Poornima

AU - Sledge, George W.

AU - Nakshatri, Harikrishna

AU - Zheng, Qi Huang

AU - Miller, Michael A.

AU - DeGrado, Timothy R

AU - Hutchins, Gary D.

AU - Sweeney, Christopher J.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - BACKGROUND. Nuclear Factor kappa B (NFκB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P). METHODS. The in vitro effects of P were assessed using the androgen independent cell line, CWR22Rv1, and human umbilical endothelial cells (HUVECs). The in vivo activity of P as a single agent and its ability to augment the efficacy of docetaxel and the anti-androgen, bicalutamide, were determined using the CWR22Rv1 xenograft model. RESULTS. Parthenolide at low micromolar concentration inhibited proliferation of CWR22Rv1 and HUVEC cells, promoted apoptosis and abrogated NFκB-DNA binding. Parthenolide downregulated anti-apoptotic genes under NFκB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). Parthenolide also augmented the in vivo efficacy of docetaxel and restored sensitivity to anti-androgen therapy. CONCLUSION. These studies demonstrate parthenolide's anti-tumor and anti-angiogenic activity, and its potential to augment the efficacy of chemotherapy and hormonal therapy.

AB - BACKGROUND. Nuclear Factor kappa B (NFκB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P). METHODS. The in vitro effects of P were assessed using the androgen independent cell line, CWR22Rv1, and human umbilical endothelial cells (HUVECs). The in vivo activity of P as a single agent and its ability to augment the efficacy of docetaxel and the anti-androgen, bicalutamide, were determined using the CWR22Rv1 xenograft model. RESULTS. Parthenolide at low micromolar concentration inhibited proliferation of CWR22Rv1 and HUVEC cells, promoted apoptosis and abrogated NFκB-DNA binding. Parthenolide downregulated anti-apoptotic genes under NFκB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). Parthenolide also augmented the in vivo efficacy of docetaxel and restored sensitivity to anti-androgen therapy. CONCLUSION. These studies demonstrate parthenolide's anti-tumor and anti-angiogenic activity, and its potential to augment the efficacy of chemotherapy and hormonal therapy.

KW - Angiogenesis

KW - Anti-tumor

KW - NFκB

KW - Parthenolide

UR - http://www.scopus.com/inward/record.url?scp=33749068887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749068887&partnerID=8YFLogxK

U2 - 10.1002/pros.20482

DO - 10.1002/pros.20482

M3 - Article

C2 - 16921510

AN - SCOPUS:33749068887

VL - 66

SP - 1498

EP - 1511

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 14

ER -